Latest news

• Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio

  Clinical stage company Arena is currently developing several innovative potential therapies for immuno-inflammatory diseases. ... He said: “Utilising Pfizer’s leading research and global development capabilities, we plan to accelerate the clinical

• Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs

  The five-year deal includes Sitryx’ two lead projects, although there’s little information available yet on the diseases targeted by those programmes as they are still in the discovery phase. ... The partnership complements Lilly’s existing focus

• MRC Technology and Peptinnovate join on bone disease

  Peptinnovate, which is developing first-in-class disease modifying medicines for immuno-inflammatory diseases, will investigate its unique peptides derived from the bacterium mycobacterium tuberculosis, the pathogen that causes TB. ... Natural peptides